Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465735 | 1.00 | CTSK (0.52) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL1784108 | 1.00 | CTSK (0.52) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL5460811 | 1.00 | CTSK (0.52) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL14168735 | 0.89 | CTSK (0.50) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL29952714 | 0.86 | PPARG (0.44) | CTSKCTSSMAPTATMPPARA | |
| SCHEMBL29955950 | 0.86 | PPARG (0.44) | CTSKCTSSMAPTATMPPARA | |
| SCHEMBL3372679 | 0.86 | AAK1 (0.43) | CTSKCTSSMAPTATM | |
| SCHEMBL14436617 | 0.86 | CTSK (0.50) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL3378239 | 0.86 | CTSK (0.46) | CTSKCTSSMAPTATM | |
| SCHEMBL27674504 | 0.86 | CTSK (0.46) | CTSKCTSSMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-109790114-B | Novel chiral ligand, metal chelate, various unnatural amino acids and synthesis method of maraviroc and key intermediate thereof | 中国科学院上海药物研究所 | 2025-03-07 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-110845288-B | Asymmetric synthesis method of chiral beta-amino aldehyde compound | 浙江工业大学 | 2022-07-19 | — | — | CN | disclosed |
| CN-110845369-B | Synthetic method of dapoxetine and intermediate thereof | 浙江工业大学 | 2022-03-18 | — | — | CN | disclosed |
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-12-29 | — | — | US | disclosed |
| CN-110845288-A | Asymmetric synthesis method of chiral β -amino aldehyde compound | 浙江工业大学 | 2020-02-28 | — | — | CN | disclosed |
| EP-3521274-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-08-07 | — | — | EP | disclosed |
| US-20190233456-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-08-01 | — | — | US | disclosed |
| CN-109790114-A | Novel chiral ligands, metallo-chelate, a variety of unnatural amino acids, the synthetic method of Malawi's promise and its key intermediate | 中国科学院上海药物研究所 | 2019-05-21 | — | — | CN | disclosed |
| EP-1448525-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004056773-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| US-20040110952-A1 | N-4-piperidinyl compounds as ccr5 modulators | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| WO-2004018425-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1368314-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | AstraZeneca AB (SE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003080574-A1 | PIPERIDINE OR 8-AZA-BICYCLO[3.2.1]OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003042178-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002070479-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
| EP-0882022-A1 | ASPARTYL PROTEASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997027180-A1 | ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | PRMT3, GRIN3A, RAMP3 | CTSK 2360/4885CTSS 1958/4885MAPT 3425/4885 |
| US-20190233456-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | PRMT3, GRIN3A, RAMP3 | CTSK 2360/4885CTSS 1958/4885MAPT 3425/4885 |
| US-20040110952-A1 | N-4-piperidinyl compounds as ccr5 modulators | CCR5, CCL5, CCR2 | CTSK 3413/4885CTSS 2413/4885MAPT 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.